The findings from this study highlight the potential of ginsenosides and their derivatives as viable candidates and protopanaxadiol as a promising lead compound for further experimental investigation as aromatase inhibitors, offering a promising alternative or adjunct to conventional breast cancer therapies. The gene discussed is CYP19A1; the disease is breast carcinoma.